User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

525

Interactions with Platform & by Email *

INTERACTIONS

105

Unique # Participated *

PARTICIPANTS

21

Responses Validated *

VALIDATIONS

9

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   A Prelude to Herpes Simplex Virus Infection.....II-1
Prevalence.....II-1
HSV Treatment.....II-1
1$100
   Patent Expiries Of Select Leading HSV Therapeutics.....II-21$100
   Leading HSV Drug (Valtrex) Sales Decline Due to Generic Competition.....II-3
Table 1: Leading Drugs in the Global Herpes Simplex Therapeutics Market (2007-2010): Value Sales for Valtrex/Zelitrex, Zovirax in US$ Million (includes corresponding Graph/Chart).....II-3
1$350
   Table 2: US Sales of Zovirax Products (2009 & 2010) in US$ Million.....II-4

Table 3: European Sales of Aldara (2008-2010) in US$ Million (includes corresponding Graph/Chart).....II-4
HSV2 Pipeline Analysis.....II-4
2$350
   Antiviral Treatment.....II-6
Major Drugs.....II-6
Valtrex (Valacyclovir).....II-6
1$100
   Table 4: Global Sales of Valtrex: 2002-2008 (includes corresponding Graph/Chart).....II-7
Zovirax (Acyclovir).....II-7
1$350
   Table 5: Global Sales Of Zovirax: 2002-2007 (includes corresponding Graph/Chart).....II-8
Famvir (Famciclovir).....II-8
Foscarnet (Foscavir).....II-8
1$350
   Abreva (Docosanol).....II-9
Cidofovir (Vistide).....II-9
Denavir/ Vectavir (Penciclovir).....II-9
Herpid.....II-9
Orajel Medicated Cold Sore Brush.....II-9
Viroxyn.....II-9
1$100
   Vaccination.....II-10
Natural Treatment.....II-10
Other Treatment.....II-10
1$100
   List of Select Pipeline Therapeutic Vaccines for the Treatment of HSV-2.....II-11
Select Clinical Trials’ Activity in the Herpes Simplex Vaccines Space.....II-11
GSK to Discontinue Development of Simplirix™.....II-11
GSK Initiates Phase III clinical Studies of Herpes Zoster Vaccine.....II-11
1$100
   Vical Presents Results from HSV-2 Vaccine Program.....II-12
BioVex Begins Phase I Clinical Trial for Immuno VEXHSV2.....II-12
1$100
   Acambis Begins Preclinical Testing of HSV Vaccine.....II-131$100
   Introduction.....II-14
Structure of Herpes Virus.....II-14
Biological Properties of Herpes Viruses.....II-14
1$100
   Different Types of Human Herpes Viruses.....II-15
Latency in Herpes Virus Family.....II-15
1$100
   Antibody Response.....II-16
HSV-1 and HSV-2 Infections.....II-16
1$100
   Causes.....II-17
The Different Types of Herpes Infections.....II-17
Oral Herpes.....II-17
Transmission.....II-17
Symptoms.....II-17
1$100
   Orolabial HSV Infections.....II-18
Recurrent Orolabial Herpetic Infection.....II-18
1$100
   Genital Infections.....II-19
Primary Genital Infection.....II-19
1$100
   Recurrent Genital Infection.....II-20
Recurrent Genital Infections in Males.....II-20
Recurrent Genital Infections in Females.....II-20
Prevention.....II-20
Diagnosis.....II-20
HSV CNS Infection.....II-20
1$100
   Herpes Gladiatorum in Adolescent Wrestlers.....II-211$100
   Acute Herpetic Infections.....II-22
Acute Herpetic Gingivostomatitis.....II-22
Acute Herpetic Pharyngotonsillitis.....II-22
1$100
   HSV Infection in Neonates.....II-23
Disseminated HSV Disease.....II-23
1$100
   Other HSV Infections.....II-24
Herpes Whitlow.....II-24
Primary Eye HSV Infection.....II-24
HSV Infections In Different Age Groups.....II-24
1$100
   HSV Infection in Pregnant Women.....II-25
HSV in Immunocompromised Patients.....II-25
1$100
   Morbidity and Mortality.....II-26
Seriousness of Herpes Simplex Infection.....II-26
Preventive Measures.....II-26
1$100
   Diagnosis of HSV Infection.....II-27
Virologic Tests.....II-27
Tzanck Smear Test.....II-27
1$100
   Polymerase Chain Reaction Tests.....II-28
Serologic Tests.....II-28
Biokit HSV-2.....II-28
HerpeSelect.....II-28
1$100
   Western Blot Test.....II-29
Type-Specific Assays Test.....II-29
Tests for Herpes Encephalitis.....II-29
Imaging Tests.....II-29
Brain Biopsy.....II-29
PCR.....II-29
1$100
   VivaGel Vaginal Microbicide.....II-30
VivaGel® Retains Anti-viral Activity Against HSV and HIV.....II-30
Simplivir™.....II-30
HerpeCide.....II-30
1$100
   NB-001.....II-31
Helicase-Primase Inhibitors.....II-31
1$100
   Medivir Launches ‘Xerese’ Cream for Cold Sores in the US.....II-32
Actavis Launches Valaciclovir in Switzerland.....II-32
Matrix Labs Receives FDA Approval for Valacyclovir Hydrochloride Tablets.....II-32
Ranbaxy Pharmaceuticals Launches Valacyclovir Hydrochloride into US Market.....II-32
1$100
   Sirion Therapeutics Secures US FDA Approval for ZirganTM 0.15%.....II-33
Meridian Life Science Introduces Herpes Simplex Virus Antigens.....II-33
1$100
   Amgen Acquires BioVex.....II-34
Antigenics Changes Name to Agenus.....II-34
Clinigen Signs Agreement with AstraZeneca for Purchase of Foscavir.....II-34
1$100
   NanoViricides Inks R&D Deal with Dr. Ken S. Rosenthal’s Laboratory.....II-35
New American Therapeutics Purchases US Rights of Denavir.....II-35
GlaxoSmithKline Acquires Xeclear Marketing Rights from Medivir.....II-35
Bausch & Lomb Acquires Zirgan® Marketing Rights for the US Market.....II-35
Genocea In-Licenses HSV Patent Estate from University of Washington.....II-35
1$100
   Medivir Teams Up with Meda for Marketing Xerese in the US.....II-36
GSK and NanoBio Ink Licensing Deal for NB-001.....II-36
Mymetics Takes Over Bestewil Holding.....II-36
Sanofi Pasteur Acquires Acambis.....II-36
1$100
   Profectus Enters into an Assignment and License Deal with Wyeth.....II-371$100
   Agenus, Inc. (US).....II-38
AiCuris GmbH & Co.KG (Germany).....II-38
Astellas Pharma, Inc. (Japan).....II-38
Clinigen Group (UK).....II-38
1$100
   Cytogenix, Inc. (US).....II-39
Genocea Biosciences (US).....II-39
GlaxoSmithKline Plc. (UK).....II-39
1$100
   Lumavita AG (Switzerland).....II-40
NanoBio Corporation (US).....II-40
1$100
   NanoViricides, Inc. (US).....II-41
Novartis International AG (Switzerland).....II-41
Sanofi (France).....II-41
1$100
   Starpharma Holdings Limited (Australia).....II-42
Vical (US).....II-42
1$100
   Table 6: World Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market by Geographic Region – US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-431$350
   Table 7: World Historic Review for Herpes Simplex Virus Treatment Market by Geographic Region – US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-441$350
   Table 8: World 15-Year Perspective for Herpes Simplex Virus Treatment Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-451$350
   A. Market Analysis.....III-1
Herpes Simplex Infection Increases in the US.....III-1
HSV Infections In Different Races.....III-1
Valtrex Dominates US HSV Prescription Market.....III-1
1$75
   Table 9: Leading Drugs in US Herpes Therapeutics Market (2011): Percentage Breakdown of New Prescriptions for Valtrex, Acyclovir, Zovirax, Aldara, Denavir, and Famvir (includes corresponding Graph/Chart).....III-2
Product Launches.....III-2
1$200
   Clinical Trials.....III-31$75
   Strategic Corporate Developments.....III-43$225
   Key Players.....III-72$150
   B. Market Analytics.....III-9
Table 10: The US Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-9
1$200
   Table 11: The US Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-101$200
   Market Analytics.....III-11
Table 12: European Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market by Geographic Region – France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-11
1$200
   Table 13: European Historic Review for Herpes Simplex Virus Treatment Market by Geographic Region – France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-121$200
   Table 14: European 15-Year Perspective for Herpes Simplex Virus Treatment Market by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-131$200
   A. Market Analysis.....III-14
Key Player.....III-14
1$75
   B. Market Analytics.....III-15
Table 15: French Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-15
1$200
   Table 16: French Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-161$200
   A. Market Analysis.....III-17
Key Player.....III-17
1$75
   B. Market Analytics.....III-18
Table 17: German Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-18
1$200
   Table 18: German Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-191$200
   Market Analytics.....III-20
Table 19: Italian Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-20
1$200
   Table 20: Italian Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
Clinical Trials.....III-22
Strategic Corporate Developments.....III-22
1$75
   Key Players.....III-232$150
   B. Market Analytics.....III-25
Table 21: The UK Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-25
1$200
   Table 22: The UK Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-261$200
   Market Analytics.....III-27
Table 23: Spanish Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-27
1$200
   Table 24: Spanish Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-281$200
   Market Analytics.....III-29
Table 25: Russian Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-29
1$200
   Table 26: Russian Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-301$200
   A. Market Analysis.....III-31
Product Launch.....III-31
Strategic Corporate Development.....III-31
Key Players.....III-31
2$150
   B. Market Analytics.....III-33
Table 27: Rest of European Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-33
1$200
   Table 28: Rest of European Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-341$200
   A. Market Analysis.....III-35
Clinical Trial.....III-35
Key Players.....III-35
1$75
   B. Market Analytics.....III-36
Table 29: Rest of World Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-36
1$200
   Table 30: Rest of World Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-371$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com